ALS drug CNM-Au8 moves to Open-Label phase: hope for slowing disease?
NCT ID NCT05299658
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study is an optional extension for people with early amyotrophic lateral sclerosis (ALS) who completed a previous placebo-controlled trial. It aims to see if the experimental drug CNM-Au8 is safe and can slow disease progression over a longer period. About 40 participants will receive the drug openly, and researchers will monitor side effects and nerve function changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Concord Hospital
Concord, New South Wales, 2139, Australia
-
Neuroscience Research Australia
Randwick, New South Wales, 2031, Australia
Conditions
Explore the condition pages connected to this study.